Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
enGene TherapeuticsFRA:S0N0 -2.05%19 Market Cap is €97.82 Mil as of Aug. 18, 2026. GuruFocus rates FRA:S0N0 with a GF Score™ of 19/100. The stock has 1 warning sign investors should review. Among 1,422 Biotechnology companies, enGene Therapeutics ranks worse than 50.84% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). enGene Therapeutics's share price for the quarter that ended in Apr. 2026 was €5.74. enGene Therapeutics's Shares Outstanding (EOP) for the quarter that ended in Apr. 2026 was 66.99 Mil. Therefore, enGene Therapeutics's market cap for the quarter that ended in Apr. 2026 was €384.52 Mil.
enGene Therapeutics's quarterly market cap
increased
from Oct. 2025 (€311.07 Mil) to Jan. 2026 (€566.06 Mil) but then
declined
from Jan. 2026 (€566.06 Mil) to Apr. 2026 (€384.52 Mil).
enGene Therapeutics's annual market cap
stayed the same
from Oct. 2023 (€0.00 Mil) to Oct. 2024 (€0.00 Mil) but then
increased
from Oct. 2024 (€0.00 Mil) to Oct. 2025 (€311.07 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. enGene Therapeutics's Enterprise Value for Today is €-96.69 Mil.
enGene Therapeutics (FRA:S0N0) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
enGene Therapeutics Market Cap Related Terms
enGene Therapeutics Market Cap Historical Data
* Premium members only.
The historical data trend for enGene Therapeutics's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:S0N0 vs VTVT, GUTS, VXRT: Market Cap Comparison
For the Biotechnology subindustry, enGene Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
enGene Therapeutics Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, enGene Therapeutics's Market Cap distribution charts can be found below:
* The bar in red indicates where enGene Therapeutics's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
enGene Therapeutics's Market Cap for the fiscal year that ended in Oct. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
enGene Therapeutics (FRA:S0N0) has a Market Cap of €97.82 Mil as of Aug. 18, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on enGene Therapeutics and its competitors. According to the industry distribution chart, enGene Therapeutics ranks #723 out of 1422 companies in the Biotechnology industry, placing it in the top 50.8%.
Is enGene Therapeutics' Market Cap too high?
enGene Therapeutics' current Market Cap is €97.82 Mil. Based on the distribution chart, enGene Therapeutics ranks #723 out of 1422 companies in the Biotechnology industry, which is below the industry midpoint. Overall, enGene Therapeutics has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does enGene Therapeutics' Market Cap compare to VTVT and GUTS?
According to the Biotechnology industry distribution chart, enGene Therapeutics ranks #723 out of 1422 companies for Market Cap. This places enGene Therapeutics in the lower half of its industry. The industry median Market Cap is 118.87. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 118.87, based on 1,422 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on enGene Therapeutics and its competitors. For the Biotechnology industry, the median Market Cap is 118.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. enGene Therapeutics's current Market Cap is €97.82 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is enGene Therapeutics stock overvalued right now?
enGene Therapeutics (FRA:S0N0) has a current Market Cap of €97.82 Mil. The current Market Cap is €97.82 Mil. enGene Therapeutics' overall GF Score™ is 19/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For enGene Therapeutics (FRA:S0N0), the current Market Cap is €97.82 Mil as of Aug. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
enGene Therapeutics Inc is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, to create new ways to address diseases with high clinical needs. Its pioneering program is detalimogene voraplasmid (also known as detalimogene) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. It is developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform.
19GF Score
Get the complete analysis for FRA:S0N0
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:S0N0 has been successfully added to your 
